Literature DB >> 26877169

Self-administered methoxyflurane for procedural analgesia: experience in a tertiary Australasian centre.

A L Gaskell1, C G Jephcott1, J R Smithells1, J W Sleigh1,2.   

Abstract

Methoxyflurane, an agent formerly used as a volatile anaesthetic but that has strong analgesic properties, will soon become available again in the UK and Europe in the form of a small hand-held inhaler. We describe our experience in the use of inhaled methoxyflurane for procedural analgesia within a large tertiary hospital. In a small pilot crossover study of patients undergoing burns-dressing procedures, self-administered methoxyflurane inhalation was preferred to ketamine-midazolam patient-controlled analgesia by five of eight patients. Patient and proceduralist outcomes and satisfaction were recorded from a subsequent case series of 173 minor surgical and radiological procedures in 123 patients performed using inhaled methoxyflurane. The procedures included change of dressing, minor debridement, colonoscopy and incision-and-drainage of abscess. There was a 97% success rate of methoxyflurane analgesia to facilitate these procedures. Limitations of methoxyflurane include maximal daily and weekly doses, and uncertainty regarding its safety in patients with pre-existing renal disease.
© 2016 The Association of Anaesthetists of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26877169     DOI: 10.1111/anae.13377

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  9 in total

Review 1.  Management of trauma pain in the emergency setting: low-dose methoxyflurane or nitrous oxide? A systematic review and indirect treatment comparison.

Authors:  Keith M Porter; Mohd Kashif Siddiqui; Ikksheta Sharma; Sara Dickerson; Alice Eberhardt
Journal:  J Pain Res       Date:  2017-12-20       Impact factor: 3.133

Review 2.  The role of inhaled methoxyflurane in acute pain management.

Authors:  Keith M Porter; Anthony D Dayan; Sara Dickerson; Paul M Middleton
Journal:  Open Access Emerg Med       Date:  2018-10-18

3.  Low-dose methoxyflurane analgesia in adolescent patients with moderate-to-severe trauma pain: a subgroup analysis of the STOP! study.

Authors:  Stuart Hartshorn; Patrick Dissmann; Frank Coffey; Mark Lomax
Journal:  J Pain Res       Date:  2019-02-15       Impact factor: 3.133

4.  Primary management of burn injuries: Balancing best practice with pragmatism.

Authors:  Nikki L Allorto
Journal:  S Afr Fam Pract (2004)       Date:  2020-09-04

5.  Usability and effectiveness of inhaled methoxyflurane for prehospital analgesia - a prospective, observational study.

Authors:  Helmut Trimmel; Alexander Egger; Reinhard Doppler; Mathias Pimiskern; Wolfgang G Voelckel
Journal:  BMC Emerg Med       Date:  2022-01-15

Review 6.  [Volatile anesthetics for prehospital analgesia by paramedics-An overview].

Authors:  Helmut Trimmel; Alexander Egger; Reinhard Doppler; Christoph Beywinkler; Wolfgang G Voelckel; Janett Kreutziger
Journal:  Anaesthesist       Date:  2021-10-18       Impact factor: 1.041

7.  Methoxyflurane Analgesia in Adult Patients in the Emergency Department: A Subgroup Analysis of a Randomized, Double-blind, Placebo-controlled Study (STOP!).

Authors:  Frank Coffey; Patrick Dissmann; Kazim Mirza; Mark Lomax
Journal:  Adv Ther       Date:  2016-08-27       Impact factor: 3.845

8.  Prospective, Multicentre Trial of Methoxyflurane for Acute Trauma-Related Pain in Helicopter Emergency Medical Systems and Hostile Environments: METEORA Protocol.

Authors:  Franco Marinangeli; Giorgio Reggiardo; Antonella Sblendido; Amedeo Soldi; Alberto Farina
Journal:  Adv Ther       Date:  2018-10-29       Impact factor: 3.845

9.  Non-interventional study evaluating exposure to inhaled, low-dose methoxyflurane experienced by hospital emergency department personnel in France.

Authors:  John Frangos; Anissa Belbachir; Sandrine Dautheville; Christiane Jung; Key Herklotz; Freya Amon; Sara Dickerson; Berangere Chomier
Journal:  BMJ Open       Date:  2020-02-10       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.